<DOC>
	<DOCNO>NCT02610556</DOCNO>
	<brief_summary>The investigator aim evaluate efficiency toxicity concurrent docetaxel cisplatin intensity-modulated radiotherapy high risk locoregionally advanced nasopharyngeal carcinoma .</brief_summary>
	<brief_title>Concurrent Docetaxel Plus Cisplatin Cisplatin Alone With IMRT High Risk Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>Eligible patient randomly assign receive intensity-modulated radiotherapy ( IMRT ) concurrent chemotherapy docetaxel plus cisplatin cisplatin alone . IMRT deliver total dose 68 Gy high 33 fraction primary tumor . Concurrent chemotherapy experimental arm consist docetaxel 60 mg/m² , D1 cisplatin 25 mg/m² , D1-3 every 3 week 3 cycle . Concurrent chemotherapy control arm consist cisplatin 100 mg/m² , D1 every 3 week 3 cycles.The primary endpoint overall survival ( OS ) , define time randomization day death cause . Secondary end point include failure-free survival ( FFS ) , locoregional relapse-free survival ( LRFS ) , distant metastasis-free survival ( DMFS ) incidence grade 3 high acute toxicity . All efficacy analysis conduct intention-to-treat population , safety population include patient receive randomly assign treatment .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Newly histologically confirm nonkeratinizing ( WHO 1991 ) nasopharyngeal carcinoma . Tumor stag T1N3M0 , T23N23M0 T4N03M0 ( 2010 UICC/AJCC stag system ) . Pretreatment EBV DNA ≥ 1500 copies/mL . Karnofsky scale ( KPS ) ≥ 70 . Adequate marrow : leucocyte count ≥ 4×10E9/L , hemoglobin ≥ 110g/L platelet count ≥ 100×10E9/L . Normal liver function test : Alanine Aminotransferase ( ALT ) , Aspartate Aminotransferase ( AST ) bilirubin ≤ 1.5×upper limit normal ( ULN ) concomitant alkaline phosphatase ( ALP ) ≤ 2.5×ULN . Adequate renal function : creatinine clearance ≥ 60 ml/min creatinine ≤ 1.5×ULN . Patients must give write informed consent . Prior malignancy , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer . Pregnancy lactation ( consider pregnancy test woman childbearing age emphasize effective contraception treatment period ) . History previous radiotherapy ( except nonmelanomatous skin cancer outside intend radiotherapy volume ) . Prior radiotherapy , chemotherapy surgery ( except diagnostic ) primary tumor node . Any severe intercurrent disease , may bring unacceptable risk affect compliance trial , example , unstable cardiac disease require treatment , renal disease , chronic hepatitis , diabetes poor control ( fast plasma glucose &gt; 1.5×ULN ) , emotional disturbance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>NPC</keyword>
	<keyword>concurrent chemotherapy</keyword>
	<keyword>docetaxel</keyword>
	<keyword>cisplatin</keyword>
</DOC>